Your browser doesn't support javascript.
loading
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.
Bailly, Sarah; Cartron, Guillaume; Chaganti, Sridhar; Córdoba, Raul; Corradini, Paolo; Düll, Johannes; Ferrarini, Isacco; Osborne, Wendy; Rosenwald, Andreas; Sancho, Juan-Manuel; Tilly, Hervé; Van Den Neste, Eric; Viardot, Andreas; Visco, Carlo.
Affiliation
  • Bailly S; Département d'Hématologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Cartron G; Department of Haematology, Centre Hospitalier Universitaire de Montpellier, UMR-CNRS 5535, Montpellier, France.
  • Chaganti S; Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK.
  • Córdoba R; Department of Hematology, Fundación Jiménez Díaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain.
  • Corradini P; Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
  • Düll J; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Ferrarini I; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Osborne W; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
  • Rosenwald A; Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
  • Sancho JM; ICO-IJC-Hospital Germans Trias I Pujol, Barcelona, Spain.
  • Tilly H; Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, Rouen, France.
  • Van Den Neste E; Département d'Hématologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Viardot A; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Visco C; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Hematol Oncol ; 40(4): 505-517, 2022 Oct.
Article in En | MEDLINE | ID: mdl-35488888
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Expert Testimony Type of study: Diagnostic_studies Limits: Humans Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Expert Testimony Type of study: Diagnostic_studies Limits: Humans Language: En Year: 2022 Type: Article